https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-09-01 / Haematologica 2002 Sep;87(9):989-1001
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-09-01 / Haematologica 2002 Sep;87(9):989-10012002-09-01 00:00:002019-02-15 08:51:09Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-09-01 / Blood 2002 Sep;100(5):1734-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-09-01 / Blood 2002 Sep;100(5):1734-412002-09-01 00:00:002019-02-15 08:44:52Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-05-30 / N. Engl. J. Med. 2002 May;346(22):1752-3
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-05-30 / N. Engl. J. Med. 2002 May;346(22):1752-32002-05-30 00:00:002019-02-15 08:35:36Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-05-01 / Br. J. Haematol. 2002 May;117(2):297-305
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-05-01 / Br. J. Haematol. 2002 May;117(2):297-3052002-05-01 00:00:002019-02-15 08:51:10Optimizing dendritic cell-based immunotherapy in multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-04-01 / Blood 2002 Apr;99(7):2512-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-04-01 / Blood 2002 Apr;99(7):2512-72002-04-01 00:00:002019-02-15 08:51:11Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-03-01 / Nat. Rev. Immunol. 2002 Mar;2(3):151-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-03-01 / Nat. Rev. Immunol. 2002 Mar;2(3):151-612002-03-01 00:00:002019-02-15 08:44:52Mouse and human dendritic cell subtypes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-03-01 / J. Clin. Endocrinol. Metab. 2002 Mar;87(3):1098-104
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-03-01 / J. Clin. Endocrinol. Metab. 2002 Mar;87(3):1098-1042002-03-01 00:00:002019-02-15 08:53:31Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-02-01 / Bone Marrow Transplant. 2002 Feb;29(3):213-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-02-01 / Bone Marrow Transplant. 2002 Feb;29(3):213-212002-02-01 00:00:002019-02-15 08:51:12Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-02-01 / Int. J. Oncol. 2002 Feb;20(2):247-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-02-01 / Int. J. Oncol. 2002 Feb;20(2):247-532002-02-01 00:00:002020-06-23 09:44:50Generation of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-01-30 / Cancer Immunol. Immunother. 2002 Apr;51(2):99-106
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-01-30 / Cancer Immunol. Immunother. 2002 Apr;51(2):99-1062002-01-30 00:00:002019-02-15 08:39:03Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen
